Literature DB >> 30542436

Overexpression of epithelial cell adhesion molecule as a predictor of poor outcome in patients with hepatocellular carcinoma.

Chih-Jan Ko1,2, Chia-Jung Li3, Meng-Yu Wu4,5, Pei-Yi Chu6,7,8.   

Abstract

Cancer growth, metastasis and development are regulated by a number of genes, whose expression mediates important processes, including cellular plasticity, motility and internal interactions in the tumor microenvironment. The epithelial cell adhesion molecule (EpCAM) serves an important role in cell-cell migration and tumorigenicity, particularly metastasis. The aim of the present study was to measure EpCAM expression using immunohistochemistry and to investigate the association between clinicopathological features and prognosis in hepatocellular carcinoma (HCC). The results revealed that EpCAM expression may be a biomarker for poor prognosis in patients with HCC and may therefore be used to predict clinical outcome. The present study suggests that EpCAM expression in HCC can be considered as a routine biomarker for unfavorable prognosis and may provide a basis for the future development of anti-EpCAM-targeted therapy.

Entities:  

Keywords:  biomarker; epithelial cell adhesion molecule; hepatocellular carcinoma

Year:  2018        PMID: 30542436      PMCID: PMC6257457          DOI: 10.3892/etm.2018.6794

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  40 in total

1.  EpCAM regulates cell cycle progression via control of cyclin D1 expression.

Authors:  A Chaves-Pérez; B Mack; D Maetzel; H Kremling; C Eggert; U Harréus; O Gires
Journal:  Oncogene       Date:  2012-03-05       Impact factor: 9.867

2.  Genetic polymorphisms in apoptosis-related genes and the prognosis of hepatocellular carcinoma.

Authors:  Guo-Peng Yu; Qian-Yi Xiao; Zhu-Qing Shi; Li-Sha Tang; Xiao-Pin Ma; Lu-Yao Zhang; Hai-Tao Chen; Wen-Jia Wang; Peng-Yin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexige Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hong-Jie Yu; Jie-Lin Sun; S Lilly Zheng; Jian-Feng Xu; Long Yu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

3.  Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.

Authors:  El Mehdi Tazi; Ismail Essadi; Hind M'rabti; Anass Touyar; Pr Hassan Errihani
Journal:  N Am J Med Sci       Date:  2011-04

4.  High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.

Authors:  Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Ronald Simon; Hanspeter Spichtin; Robert Maurer; Urs Metzger; Brida von Castelberg; Rahel Bart; Shanna Stopatschinskaya; Ossi Robert Köchli; Philip Haas; Friedrich Mross; Markus Zuber; Holger Dietrich; Susanne Bischoff; Martina Mirlacher; Guido Sauter; Guenther Gastl
Journal:  Breast Cancer Res Treat       Date:  2004-08       Impact factor: 4.872

5.  Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

Authors:  Gilbert Spizzo; Philip Went; Stephan Dirnhofer; Peter Obrist; Holger Moch; Patrick A Baeuerle; Elisabeth Mueller-Holzner; Christian Marth; Guenther Gastl; Alain G Zeimet
Journal:  Gynecol Oncol       Date:  2006-05-06       Impact factor: 5.482

6.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

Authors:  Taro Yamashita; Marshonna Forgues; Wei Wang; Jin Woo Kim; Qinghai Ye; Huliang Jia; Anuradha Budhu; Krista A Zanetti; Yidong Chen; Lun-Xiu Qin; Zhao-You Tang; Xin Wei Wang
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

7.  Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.

Authors:  Yan Zhou; Beili Wang; Jiong Wu; Chunyan Zhang; Yiwen Zhou; XinRong Yang; Jian Zhou; Wei Guo; Jia Fan
Journal:  BMC Cancer       Date:  2016-07-20       Impact factor: 4.430

8.  Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan.

Authors:  Tsung-Hsing Hung; Chih-Ming Liang; Chien-Ning Hsu; Wei-Chen Tai; Kai-Lung Tsai; Ming-Kun Ku; Jiunn-Wei Wang; Kuo-Lun Tseng; Lan-Ting Yuan; Seng-Howe Nguang; Shih-Cheng Yang; Cheng-Kun Wu; Pin-I Hsu; Deng-Chyang Wu; Seng-Kee Chuah
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

9.  Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.

Authors:  H-C Yu; M-H Hung; Y-L Chen; P-Y Chu; C-Y Wang; T-T Chao; C-Y Liu; C-W Shiau; K-F Chen
Journal:  Cell Death Dis       Date:  2014-07-31       Impact factor: 8.469

10.  Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties.

Authors:  Jialin Cai; Bin Li; Yan Zhu; Xuqian Fang; Mingyu Zhu; Mingjie Wang; Shupeng Liu; Xiaoqing Jiang; Jianming Zheng; XinXin Zhang; Peizhan Chen
Journal:  EBioMedicine       Date:  2017-04-12       Impact factor: 8.143

View more
  7 in total

1.  Overexpression of LGR-5 as a Predictor of Poor Outcome in Patients with Hepatocellular Carcinoma.

Authors:  Chih-Jan Ko; Chia-Jung Li; Meng-Yu Wu; Pei-Yi Chu
Journal:  Int J Environ Res Public Health       Date:  2019-05-23       Impact factor: 3.390

2.  A Newly Established Murine Cell Line as a Model for Hepatocellular Cancer in Non-Alcoholic Steatohepatitis.

Authors:  Andreas Kroh; Jeanette Walter; Herdit Schüler; Jochen Nolting; Roman Eickhoff; Daniel Heise; Ulf Peter Neumann; Thorsten Cramer; Tom Florian Ulmer; Athanassios Fragoulis
Journal:  Int J Mol Sci       Date:  2019-11-12       Impact factor: 5.923

Review 3.  Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.

Authors:  Keyur Patel; Ryan Lamm; Peter Altshuler; Hien Dang; Ashesh P Shah
Journal:  Int J Mol Sci       Date:  2020-09-15       Impact factor: 5.923

4.  rs62139665 Polymorphism in the Promoter Region of EpCAM Is Associated With Hepatitis C Virus-Related Hepatocellular Carcinoma Risk in Egyptians.

Authors:  Tarek Mohamed Kamal Motawi; Nermin Abdel Hamid Sadik; Dina Sabry; Sally Atef Fahim; Nancy Nabil Shahin
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

Review 5.  The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.

Authors:  Zhang Guizhen; Ji Guanchang; Liu Liwen; Wang Huifen; Ren Zhigang; Sun Ranran; Yu Zujiang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-25       Impact factor: 6.055

Review 6.  Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies.

Authors:  Yu-Chin Liu; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Cells       Date:  2020-05-26       Impact factor: 6.600

Review 7.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.